Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Magnetic Heart Pump Helps Heart Failure Patients

By HospiMedica International staff writers
Posted on 31 Oct 2018
An innovative left ventricular assist device (LVAD) can help advanced heart failure (HF) patients who are not eligible for heart transplants enjoy a better quality of life for the rest of their days.

The Abbott (Abbott Park, IL, USA) HeartMate 3 consists of a magnetically levitated (MagLev) centrifugal-flow pump implanted above the diaphragm, next to the native heart; the pump is attached to the aorta, thus leaving natural circulation in place. More...
The system can pump up to 10 liters of blood per minute, using magnets keep the rotor in place, reducing trauma to blood cells passing through the pump while improving flow. The pump also adds consistently timed flow gaps in order to generate an artificial pulse which further reduces adverse events, including combating the formation of thrombii.

The MagLev system is calibrated tens of thousands of times per second to ensure it stays suspended and centered within the pump, no matter the speed settings used by a physician, ensuring that the pump is performing effectively. The patient himself wears an external, wearable controller, the system driveline, and a battery that powers the pump. Recent clinical data shows that patients implanted with the Abbot HeartMate 3 LVAD enjoyed a survival rate of 82.8% at two years follow-up, and that rates of suspected pump thrombosis were just 1.1% at two years.

“We partner with physicians to holistically develop therapies that benefit patients and achieve better outcomes,” said Mike Pederson, senior vice president of Abbott's Cardiac Arrhythmias and HF business. “The unique design of the HeartMate 3 LVAD, with its full MagLev technology, takes an established innovation and improves upon it in meaningful ways to help people with advanced heart failure live fuller lives.”

“Approximately a quarter of a million people are living with advanced heart failure, and many of these people will need a heart transplant; however, only a few thousand will receive a new heart,” said Nir Uriel, MD, of the University of Chicago Medicine (IL, USA). “Destination therapy approval for Abbott's HeartMate 3 device now gives these patients new hope that they can receive a heart pump clinically proven to mitigate challenges we've historically confronted with this therapy—stroke and blood clotting—while also offering survival rates on par with transplant.”

An LVAD is intended to complement a weakened heart by providing circulatory support, thus helping to maintain or improve blood flow to the kidneys, liver, brain and other organs. One end is attached to the left ventricle, and other is attached to the aorta; blood flows from the ventricles into the pump and is then ejected out of the device and into the aorta. LVADs are used as destination therapy or as a bridge-to-transplant, allowing the patient to be discharged from the hospital and lead a more normal and fuller life.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.